Breakthroughs in Cardio-Oncology: Summit Highlights New Approaches to Protecting Hearts During Cancer Treatment
Table of Contents
A growing field dedicated to mitigating the cardiovascular complications of cancer therapy saw notable advancements presented at the Global Cardio-Oncology Summit (GCOS) held October 30 to November 1 in Cape Town, South Africa. The annual conference, organized by the International Cardio-Oncology Society (IC-OS), brought together leading experts to address the complex intersection of oncology and cardiology, focusing on innovative prevention and management strategies.
The summit underscored a critical shift in how clinicians approach cancer treatment, recognizing that protecting the heart is paramount alongside fighting the disease. Experts emphasized the need for proactive cardiac monitoring, personalized treatment plans, and a greater understanding of the mechanisms driving cardiac toxicity.
A key warning issued at the summit was to avoid intravenous iron in patients receiving anthracyclines.
Dr. Ruth Plummer, in a keynote lecture on the development of new cancer drugs, articulated a new philosophy regarding dosage. “We ‘grow up’: the maximum tolerated dose is not always the optimal dose,” she stated, advocating for a more nuanced approach to drug administration. Plummer stressed the importance of obsessive and continuous cardiac monitoring, meticulous tracking and evaluation of all toxicities, and alignment with established guidelines – specifically, the European Society of Cardiology (ESC) cardio-oncology guidelines – to ensure patient safety.
The future of cancer treatment, as presented at the summit, is increasingly focused on precision. Innovations like antibody-drug conjugates, immunotherapy (including bispecifics), and genomic profiling are offering targeted therapies with the potential to minimize collateral damage to the cardiovascular system.
the crucial Role of Primary Care
The summit also emphasized the vital role of primary care physicians in cardio-oncology. Experts noted that thes physicians are frequently enough the first point of contact for patients experiencing cardiovascular side effects from cancer therapy. “Early recognition of cardiovascular – and systemic – side effects of cancer therapy requires education,” one presenter emphasized. The challenge lies in accurately diagnosing these effects, as the context of cancer treatment significantly alters the differential diagnosis. A call to action resonated throughout the session: to inspire healthcare professionals to become “International Agents of Change.”
Addressing Cardio-Oncology Challenges in Africa
A dedicated session focused on the unique challenges and opportunities for cardio-oncology across Africa. Presentations from souhila Ouabdesselam (Algeria), Dr. Kieran Mwazo (Kenya), Nana Poku (Ghana/Switzerland), and Trishun Singh (south Africa) revealed a common struggle to transition from a focus on infectious diseases to addressing the growing burden of chronic cardiovascular disease and cancer.
Key challenges identified included:
- Limited resources for both treatment and prevention.
- Inadequate specialist training in emerging fields.
- A lack of standardized cardio-oncology programs.
though, the session also highlighted promising avenues for progress, including strengthening preventive medicine, prioritizing cardiovascular risk factor modification, empowering pharmacists as key patient contacts, and fostering political will for long-term strategic implementation.
Advancements in Thrombosis Management
New insights into managing venous thromboembolism (VTE) in cancer patients were also presented. Research stemming from the API-CAT trial suggests that extended anticoagulation with a reduced dose of apixaban is non-inferior to a full dose in preventing recurrent VTE, representing a step forward in personalized care for this complex patient population.
The Global Cardio-Oncology Summit 2025 underscored a growing commitment to protecting the hearts of cancer patients. As cancer treatments become more complex, the field of cardio-oncology will undoubtedly play an increasingly critical role in ensuring that patients not only survive cancer but thrive afterward.
